Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 718.25, up by 11.95 points or 1.69% from its previous closing of Rs. 706.30 on the BSE.

The scrip opened at Rs. 709.80 and has touched a high and low of Rs. 718.50 and Rs. 707.75 respectively. So far 123751 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 721.95 and Rs. 681.00 respectively. The current market cap of the company is Rs. 172445.08 crore.

The promoters holding in the company stood at 54.97%, while institutions and non-institutions held 33.34% and 11.68% respectively.

Sun Pharmaceutical Industries has launched BromSite (bromfenac ophthalmic solution) 0.075% in the US market. A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division. BromSite is the first branded product launched by the company in the USA, following its focus on Specialty Business.

Approved by US Food and Drug Administration (USFDA) on April 8, 2016, BromSite (bromfenac ophthalmic solution) 0.075% is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery.

Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.